Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
MARGetuximab Or Trastuzumab (MARGOT) (MARGOT)
Complete Title: MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients with Stage II-III HER2-positive Breast Cancer
Trial Phase: II
Investigator: Rachel Yung
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: Paclitaxel, Pertzumab and Margetuximab (Margenza) Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
Keywords:
- Breast Cancer
- HER2-Positive
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Rachel Yung
RG1121280
NCT04425018
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients with Stage II-III HER2-positive Breast Cancer
Breast Cancer
HER2-Positive